PapMV 纳米颗粒可增强对三价灭活流感疫苗的黏膜免疫应答。

PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine.

机构信息

Department of Microbiology, Infectiology and Immunology, 'Centre de recherche en Infectiologie', Laval University, 2705 boul, Laurier, Quebec City, PQ G1V 4G2, Canada.

出版信息

J Nanobiotechnology. 2014 May 3;12:19. doi: 10.1186/1477-3155-12-19.

DOI:10.1186/1477-3155-12-19

PMID:24885884

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4022981/

Abstract

BACKGROUND

Trivalent inactivated flu vaccines (TIV) are currently the best means to prevent influenza infections. However, the protection provided by TIV is partial (about 50%) and it is needed to improve the efficacy of protection. Since the respiratory tract is the main site of influenza replications, a vaccine that triggers mucosal immunity in this region can potentially improve protection against this disease. Recently, PapMV nanoparticles used as an adjuvant in a formulation with TIV administered by the subcutaneous route have shown improving the immune response directed to the TIV and protection against an influenza challenge.

FINDINGS

In the present study, we showed that intranasal instillation with a formulation containing TIV and PapMV nanoparticles significantly increase the amount of IgG, IgG2a and IgA in lungs of vaccinated mice as compared to mice that received TIV only. Instillation with the adjuvanted formulation leads to a more robust protection against an influenza infection with a strain that is lethal to mice vaccinated with the TIV.

CONCLUSIONS

We demonstrate for the first time that PapMV nanoparticles are an effective and potent mucosal adjuvant for vaccination.

摘要

背景

三价灭活流感疫苗（TIV）是目前预防流感感染的最佳手段。然而，TIV 提供的保护是部分的（约 50%），需要提高保护效果。由于呼吸道是流感复制的主要部位，因此能够在该区域引发黏膜免疫的疫苗可能会潜在改善对这种疾病的保护。最近，PapMV 纳米颗粒作为佐剂与皮下途径给予的 TIV 联合使用，已显示出改善针对 TIV 的免疫反应并预防流感挑战的作用。